Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.

1 report, 1 independent Updated Aug 19

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Pfizer GSK

Keep exploring

Part of

Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval. All 2 developments

The entities involved

Pfizer
American multinational pharmaceutical and biotechnology corporation
- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Sat 22:36
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Fri 23:48
GSK
British multinational pharmaceutical and biotechnology company
- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Fri 07:57
- GSK out-licensed the commercialization rights for Spero Therapeutics' first drug.Fri 07:57

Related events

FDA and Pfizer are seeking regulatory approval for their products.Aug 29

Coverage

Newest first; wire copies grouped

Aug 19fool.com